Found: 11
Select item for more details and to access through your institution.
Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.
- Published in:
- PLoS ONE, 2015, v. 10, n. 6, p. 1, doi. 10.1371/journal.pone.0128816
- By:
- Publication type:
- Article
<sup>177</sup>Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice.
- Published in:
- PLoS ONE, 2014, v. 9, n. 7, p. 1, doi. 10.1371/journal.pone.0103070
- By:
- Publication type:
- Article
Combination of <sup>177</sup>Lu‐lilotomab with rituximab significantly improves the therapeutic outcome in preclinical models of non‐Hodgkin's lymphoma.
- Published in:
- European Journal of Haematology, 2018, v. 101, n. 4, p. 522, doi. 10.1111/ejh.13139
- By:
- Publication type:
- Article
<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin's lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 12, p. 1, doi. 10.2967/jnumed.119.237230
- By:
- Publication type:
- Article
<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non- Hodgkin's lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 11, p. 1, doi. 10.2967/jnumed.119.237230
- By:
- Publication type:
- Article
<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 9, p. 1, doi. 10.2967/jnumed.119.237230
- By:
- Publication type:
- Article
<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 8, p. 1, doi. 10.2967/jnumed.119.237230
- By:
- Publication type:
- Article
<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 7, p. 1, doi. 10.2967/jnumed.119.237230
- By:
- Publication type:
- Article
<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin’s lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 6, p. 1, doi. 10.2967/jnumed.119.237230
- By:
- Publication type:
- Article
<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 5, p. 1, doi. 10.2967/jnumed.119.237230
- By:
- Publication type:
- Article
<sup>177</sup>Lu-lilotomab satetraxetan has the potential to counteract resistance to rituximab in non-Hodgkin's lymphoma.
- Published in:
- Journal of Nuclear Medicine, 2020, v. 61, n. 4, p. 1, doi. 10.2967/jnumed.119.237230
- By:
- Publication type:
- Article